Equillium Inc.

0.82
0.05 (6.08%)
At close: Mar 24, 2025, 3:55 PM
0.81
-1.01%
After-hours: Mar 24, 2025, 07:55 PM EDT
6.08%
Bid 0.79
Market Cap 28.92M
Revenue (ttm) 45.92M
Net Income (ttm) -4.62M
EPS (ttm) -0.12
PE Ratio (ttm) -6.8
Forward PE -0.63
Analyst Hold
Ask 0.83
Volume 64,897
Avg. Volume (20D) 831,786
Open 0.76
Previous Close 0.77
Day's Range 0.76 - 0.82
52-Week Range 0.49 - 2.90
Beta 1.87

About EQ

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 12, 2018
Employees 45
Stock Exchange NASDAQ
Ticker Symbol EQ
Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for EQ stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 512.59% from the latest price.

Stock Forecasts
1 month ago
+33.03%
Equillium shares are trading higher after the comp... Unlock content with Pro Subscription
4 months ago
-12.33%
Equillium shares are trading lower after the company reported worse-than-expected Q3 sales results.